Lilly gets traditional FDA approval for Retevmo for thyroid cancer
by
Contributor since / Followers
Contributor since / Followers
2 months ago
jetcityimage/iStock Editorial via Getty Images
- Eli Lilly (NYSE:LLY) has received traditional approval for its drug Retevmo for the treatment of a type of thyroid cancer.
- The FDA approved the product for the treatment of advanced or metastatic medullary thyroid cancer with a RET mutation, as detected by an FDA-approved test, for patients aged two years and older, according to the FDA’s website.
- The agency first granted accelerated approval for the drug for patients 12 years and older in 2020.